Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01) | PA 17 283

Opportunity Information: Apply for PA 17 283

The National Institutes of Health (NIH) grant opportunity titled "Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01)" (Funding Opportunity Number: PA-17-283) supports research projects that tackle a growing and clinically serious overlap: tuberculosis (TB), type 2 diabetes mellitus (T2DM, including pre-diabetes), and HIV. The central problem behind the announcement is that T2DM and pre-diabetes can disrupt both innate and adaptive immune responses in ways that make people more likely to progress from latent TB infection to active disease, and once active TB develops, to experience more severe illness, poorer treatment outcomes, relapse, and higher risk of death. These risks can be even more pronounced in settings where HIV co-infection is present, because HIV already compromises immune function and complicates TB management. Through the R01 mechanism, the FOA is essentially asking investigators to generate new, actionable scientific knowledge that can lead to better therapeutic strategies and improved clinical outcomes for populations affected by this three-way convergence.

The scientific emphasis is on immune dysregulation: how metabolic disease states like T2DM and pre-diabetes alter immune pathways that normally contain Mycobacterium tuberculosis, and how those alterations interact with HIV-related immune impairment. The FOA highlights both arms of immunity, meaning it is interested in mechanisms involving early, non-specific defenses (innate immunity) as well as longer-term, antigen-specific responses (adaptive immunity). The intention is not only to describe associations, but to foster innovative research that clarifies cause-and-effect mechanisms and identifies intervention points that could be targeted with therapeutics or adjunctive treatment approaches. In practical terms, the kind of work this announcement is designed to stimulate could include discovering which immune pathways are most disrupted by dysglycemia, how those disruptions change TB pathology and bacterial control, why treatment failure or relapse becomes more common, and what strategies could counteract those effects, particularly in people living with HIV.

From an administrative standpoint, this is a discretionary NIH grant using the R01 research project grant mechanism. It falls under health-related funding activity categories and is associated with CFDA numbers 93.847, 93.855, and 93.856. The original posting date for the opportunity was May 12, 2017, and the original closing date listed in the provided data is September 7, 2020. The summary information provided does not specify an award ceiling or the expected number of awards, which typically means applicants would need to consult the full FOA and related NIH institute guidance for budget expectations, project period norms, and any institute-specific paylines or constraints.

Eligibility is broad and includes many types of U.S.-based and international organizations, which is important given that TB and HIV burdens are often highest outside the United States and that multi-site or international collaborations are commonly necessary for clinically meaningful TB/T2DM/HIV research. Eligible applicants include state, county, city, township, and special district governments; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; public and state-controlled universities; private institutions of higher education; independent school districts; nonprofits both with and without 501(c)(3) status (as long as they are not institutions of higher education in those nonprofit categories); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly highlights additional eligible applicant groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, tribal governments that are not federally recognized, and non-domestic (non-U.S.) entities/foreign organizations. This breadth signals an interest in inclusive participation and in supporting research capacity across diverse institutional settings, including those serving populations that may be disproportionately affected by diabetes, TB exposure, and HIV.

Overall, the opportunity is focused on moving beyond siloed approaches to TB, diabetes, and HIV by funding research that treats them as intersecting epidemics with shared biological and clinical consequences. The goal is to enable studies that can explain why T2DM and pre-diabetes worsen TB risk and outcomes, especially with HIV co-infection, and to translate that understanding into therapeutic strategies that reduce reactivation, severity, treatment failure, relapse, and mortality.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847, 93.855, 93.856.
• This funding opportunity was created on 2017-05-12.
• Applicants must submit their applications by 2020-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 17 283

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: